Key result
Admission body temperature <36°C in worsening heart failure is linked to ~35% higher composite risk.
Why the study?
Risk stratification in patients admitted with worsening heart failure is essential but existing models require laboratory and imaging results not routinely available; body temperature may be a simple prognostic marker.
Does low body temperature predict adverse outcomes in patients admitted with worsening heart failure?
RCT (n=4,133)
double-blind
randomized
Does low body temperature predict adverse outcomes in patients admitted with worsening heart failure?
Answers are grounded in this paper and cite their sources.
Low body temperature on admission is an independent predictor of worse cardiovascular outcomes in patients with worsening heart failure and reduced ejection fraction.
Aims Risk stratification in patients admitted with worsening heart failure (HF) is essential for tailoring therapy and counselling. Risk models are available but rarely used, in part because many require laboratory and imaging results that are not routinely available. Body temperature is associated with prognosis in other illnesses, and we hypothesized that low body temperature would be associated with worse outcomes in patients admitted with worsening HF. Methods and results The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial was an event-driven, randomized, double-blind, placebo-controlled study of tolvaptan in 4133 patients hospitalized for worsening HF with an EF <40%. Co-primary endpoints were all-cause mortality and cardiovascular (CV) death or HF rehospitalization. Body temperature was measured orally at randomization and entered in analyses both as a continuous variable and categorized into three groups (<36°C, 36–36.5°C, and >36.5°C) using Cox regression models. The composite of CV death or HF rehospitalization occurred in 1544 patients within 1 year. For every 1°C decrease in body temperature, the risk of adverse outcomes increased by 16% [hazard raio (HR) 1.16, 95% confidence interval (CI) 1.04–1.28], after adjustment for age, gender, race, systolic blood pressure, EF, blood urea nitrogen, and serum sodium. In fully adjusted analysis, the risk of adverse outcomes in the lowest body temperature group (<36°C) was 51% higher than that of the index group (>36.5°C) (HR 1.35, 95% CI 1.15–1.58). Conclusions Low body temperature is an independent marker of poor cardiovascular outcomes in patients admitted with worsening HF and reduced EF.
No takes yet. Share an insight, caveat, or question.
Payvar et al. (2013) conducted an RCT in Worsening heart failure (n=4,133). Low body temperature (<36°C) vs. Body temperature >36.5°C was evaluated on Composite of cardiovascular death or heart failure rehospitalization (HR 1.35, 95% CI 1.15-1.58). Low body temperature (<36°C) at admission for worsening heart failure increased the risk of cardiovascular.
Synapse has enriched 10 related papers. Consider them for comparative context: